MarketInOut Stock Screener Log In | Sign Up
 

Actuate Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/04/2026 16:00
Actuate Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization71.14 mln
Float8.27 mln
Earnings Date05/15/2026

Piotroski F-Score

4 / 9
Borderline

1-Year Estimate

13.50
Transformational upside

Relative Strength

93 / 100
Top performer

Business Description

Actuate Therapeutics is a Fort Worth, Texas-based company focused on developing new cancer treatments. Its main drug, elraglusib, is currently being tested in clinical trials for several difficult-to-treat cancers, including advanced pancreatic cancer and certain childhood cancers such as Ewing sarcoma, neuroblastoma, and pediatric leukemias. The company was founded in 2015 and has been building its research pipeline with the goal of bringing more effective options to patients with limited treatment choices.

Key Fundamentals

EPS-1.06
ROE-990
ROIC-1,803
ROA-212
EBITDA-22.21
EV / EBITDA-3.45
EV / EBIT-3.45

Financial Strength

Piotroski F-Score 4 / 9
1-Year Target Price13.50
Short Ratio7.05
Short % of Float8.92

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.51% 82 / 100   
1 Month 18.95% 86 / 100   
2 Months -45.27% 7 / 100   
6 Months -55.17% 9 / 100   
1 Year -68.95% 7 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us